Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-75348780 + JNJ-87801493 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-75348780 | CD3 Antibody 119 | JNJ-75348780 is a bi-specific antibody targeting CD3 and CD22, which may lead to cytotoxic immune response against B-cell tumors (NCI Thesaurus). | ||
| JNJ-87801493 | JNJ 87801493|JNJ87801493 | CD20 Antibody 26 CD28 Antibody 12 | JNJ-87801493 is a bispecific antibody targeting CD20 on B-cells and CD28 on T-cells, which potentially enhances T-cell activation and inhibits tumor growth (Blood (2024) 144 (Supplement 1): 1408). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06139406 | Phase I | JNJ-80948543 + JNJ-87801493 JNJ-75348780 + JNJ-87801493 | A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer | Recruiting | ISR | ESP | DNK | AUS | 0 |